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Human plasma LDL exhibits a diffuse fluorescence (excitation 360 nm) in the 400-600 nm range. Applica- 
tion of three-dimensional f uorescence spectroscopy shows the presence of 7 fluorophores in the lipid and 
6 fluorophores in the protein domain. The 430 nm fluorescence in freshly prepared LDL and its apo-B is 
most likely indicative for remnants of in vivo lipid peroxidation. 
Three-dimensionaljluorescence spectroscopy LDL Lipidperoxidation 
1. INTRODUCTION 
Human plasma and aortic low density lipopro- 
teins (LDL) possess a native fluorescence in the 
ultraviolet (UV) region due to tryptophan residues 
contained in apolipoprotein-B (apo-B) [l-3]. This 
fluorescence and its quenching were used to study 
some aspects of the LDL structure [2] and the 
change induced by lipid peroxidation [3]. Dobret- 
sov et al. [l] reported on the fluorescence of aortic 
LDL in the near-UV and visible regions which was 
attributed to the presence of lipid peroxidation 
products and Schuh et al. [4] found that plasma 
LDL develops a fluorescent chromophore at 
around 450 nm, when subjected in vitro to auto- 
oxidation conditions. We have shown [5] that 
native plasma LDL also exhibits fluorescence in 
the region 400-600 nm. However, the broad and 
diffuse shape of the spectrum did not allow conclu- 
sions to be made regarding the number of fluores- 
cent LDL constituents and their possible origin. 
Here, we report on the application of 
3-dimensional fluorescence spectroscopy to resolve 
the multi-fluorescent component system of the 
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LDL complex in the 390-590 nm emission range. 
The results indicate that at least one fluorophore in 
native plasma LDL may be due to lipid peroxida- 
tion. Since modification of plasma LDL by in vivo 
lipid peroxidation is frequently discussed as a 
significant event in atherogenesis [6,7], our results 
might be important for a better understanding of 
the complex phenomena occurring during lipid 
peroxidation-linked alterations of LDL. 
2. MATERIALS AND METHODS 
Human plasma LDL was prepared by step-wise 
ultracentrifugation within a density cut-off of d = 
1.020- 1.050 g/cm3 as described [S]. Four prepara- 
tions were used, of which two were from pooled 
plasma of 5 healthy, male and female donors 
under 25 years of age (LDL nos 2,3) and two from 
single donors, both female under 25 years of age 
(LDL nos 1,4). EDTA (1 mg/ml) was present 
throughout all steps of the preparation. Im- 
mediately after drawing blood, plasma was made 
200 PM in butylated hydroxytoluene. LDL 
prepared under these conditions revealed the same 
electrophoretic mobility on agarose gel elec- 
trophoresis (Lipidophor, kindly supplied by Im- 
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muno AG Vienna, Austria) as the LDL in the 
parent plasma stored at 4°C for the time needed 
for LDL preparation (5 days). In 3.75% SDS- 
PAGE (staining with Coomassie blue R250) only 
the apo-B 100 band was detectable in freshly 
prepared LDL [8]. For fluorescence measurements 
LDL was immediately dialyzed for 48 h at 4°C 
against degassed 0.01 M phosphate buffer (pH 
7.4) containing 0.16 M NaCl, 1 mg/ml EDTA and 
0.1 mg/ml chloramphenicol. The sample was 
diluted with the dialysis buffer to a final concen- 
tration of 1.5 mg total LDL/ml and the spectra 
were then recorded. The LDL lipid fraction was 
prepared by extracting 3 ml LDL solution 
(1.5 mg/ml), prepared as described above, 4 times 
with 2 ml of a mixture of CHClj/CHjOH (2: 1, 
v/v). Phase separation was facilitated by cen- 
trifugation. The pooled extract was concentrated 
to 3 ml by gassing with nitrogen and this lipid solu- 
tion was then used for fluorescence measurements. 
The aqueous phase of the chloroform/methanol 
extraction was removed and the precipitated apo-B 
washed in centrifuge tubes twice with 3 ml water, 
dried under nitrogen and redissolved in 3 ml of 3% 
aqueous SDS. This solution of apo-B was then 
used for the fluorescence spectroscopy. 
Auto-oxidation of LDL was performed essen- 
tially as described by Schuh et al. [4]. Freshly 
prepared LDL was freed from EDTA by dialysis 
against 0.01 M phosphate buffer (pH 7.4) contain- 
ing 0.16 M NaCl and 0.1 mg/ml chloramphenicol. 
The LDL was then adjusted to 1.5 mg/ml, 
transferred to a dialysis bag and placed in a 3-fold 
amount of the above-described dialysis buffer 
which was continuously gassed with oxygen. The 
auto-oxidation in the dialysis bag was performed 
at room temperature and lasted 24 h. Thereafter, 
fluorescence spectra of the total LDL complex, 
lipid and apo-B fraction were recorded. The con- 
centrations in the final measuring solutions were 
always equivalent o 1.5 mg parent LDL/ml. 
Fluorescence spectra were scanned on a Jobin 
Yvon JY3 D spectrofluorimeter. A slit width of 
10 nm was used. The instrument was standardized 
with quinine sulfate (0.1 pg/ml in 0.1 N H2SO4) to 
give a fluorescence intensity of 100 at 450 nm when 
excitation was done at 350 nm. For 3-dimensional 
fluorescence studies the samples were diluted 1: 1 
with the respective solvent. The absorbance of 
these solutions did not exceed 0.2 in the range 
300-500 nm. The contour plots (to which we refer 
as fluorescence intensity topograms, FITS) in the 
300-500 nm excitation and 390-590 nm emission 
ranges were obtained on an Aminco SPF-500 spec- 
trofluorimeter as in [9]. Band passes of the instru- 
ment were 10 nm in excitation and emission. The 
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Fig. 1. Uncorrected emission spectrum (a) at 360 nm excitation and solvent background corrected FIT (b) of total LDL 
isolated from pooled plasma (LDL no.3). (x) Probable positions of the intensity maxima. 
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elements of the excitation/emission matrix were 
acquired with IO-nm increments of both emission 
and excitation wavelengths. Solvent background 
correction was achieved by subtracting the excita- 
tion/emission matrix of the solvent from that of 
the sample. The contour lines were from 5 to 95% 
in 5% increments of the highest peak. 
3. RESULTS 
Freshly prepared human plasma LDL exhibits a 
weak fluorescence in the visible range 
(400-600 nm) when excitation is performed at 
360 nm (fig-la). The spectrum shows an apparent 
maximum at around 470 nm and shoulders at 430 
and 520 nm. The sharp peak at 410 nm is not due 
to a fluorescent chromophore but to Raman scat- 
tering. The LDL also gives a strong UV 
fluorescence, typical for tryptophan-containing 
proteins with an emission maximum at 342 nm and 
an excitation maximum at 290 nm (not shown). 
Spectra similar to that shown in fig. la were found 
for the other 3 plasma LDL samples analyzed. At 
a fixed concentration of 1.5 mg/ml the relative 
fluorescence intensity at 470 nm varied from 27.0 
to 40.0 intensity units, and at 430 nm from 22.0 to 
30.0. 
460 
A much deeper insight into the fluorescence 
characteristics of LDL was obtained by 
3-dimensional fluorescence spectroscopy. This 
technique gives a plot of fluorescence intensity as 
a function of both excitation and emission 
wavelengths. The superiority of this method is 
clearly evident from the FIT shown in fig.lb, 
which was measured with the same LDL sample 
used for the spectrum shown in fig.la. From the 
FIT it is obvious that the predominant fluorescent 
component of LDL possesses an excitation max- 
imum at 370 nm and an emission maximum at 
470 nm. 
As against a single fluorobhore the LDL pattern 
is not characterized by symmetrical contour lines 
in the FIT it is understood that LDL contains 
several fluorophores. A more detailed inspection 
of the shape of the contour lines reveals at least 4 
additional fluorophores with excitation and emis- 
sion maxima at 3551470, 355/430, 3801540 and 
400/490 nm. The diagonal lines from 350/390 to 
500/520 nm are contributions from stray light 
which could not be removed quantitatively by 
background subtraction. 
To determine whether the fluorescence is 
associated with the lipid and/or protein portion of 
LDL the two components were separated and 
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Fig.2. Uncorrected emission spectra {a) at 360 nm excitation and sofvent background corrected FIT (b) of the LDL lipid 
material. The emission spectra were obtained from the lipids of LDLs from plasma of two single donors (nos 1,4) and 
two from pooled plasma (nos 2,3). The FIT was recorded from the lipid material of LDL no.3. (x) As in fig.1. 
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analyzed again. The spectra shown in figs 2a and sion spectrum (excitation 360 nm) and the FIT of 
3a indicate that fluorophores are contained in both a freshly prepared LDL were identical with the 
fractions. The apparent emission maxima iden- spectra recorded from the same preparation but 
tified in the spectra are at 470 and 520 nm in the stored at 4°C under nitrogen for 3 weeks as a 4% 
lipid fraction and at 415 (Raman band), 440 and solution in 0.1 M Tris-HCI buffer (pH 7.5) con- 
520 nm in the apo-B fraction. The lipid and apo-B taining 1 mg/ml EDTA. It was ascertained that 
fractions from all 4 LDL samples resulted in more fluorescence did not result from contaminants in 
or less the same spectral form with some variation the buffers and chemicals used for isolation of 
in the relative fluorescence intensity. LDL. 
Representative FITS for the lipid and protein 
fraction of LDL are shown in figs 2b and 3b. Ac- 
cording to these topograms the lipid fraction con- 
tains a major fluorescent chromophore with spec- 
tral properties (excitation maximum/emission 
maximum) at 356/462 nm. Several minor 
fluorophores are at 350/490, 375/460, 3701530, 
355/430 and 400/470 nm. The shape of the FIT is 
also indicative of a further fluorescent component 
possessing a maximum at about 325/390 nm 
which, however, is just at the short-wavelength 
limit or even outside the measured range. The pro- 
tein fraction (fig.3b) possesses main fluorophores 
with coordinates at 330/390, 3551430 and 
365/460 nm and additional fluorophores with low 
fluorescence intensity at 3801540, 400/530 and 
420/490 nm. 
The fluorescence properties of native LDL did 
not change upon storage at 4°C. Thus, the emis- 
When the LDL was subjected to conditions 
known to induce auto-oxidative degradation of 
polyunsaturated lipids, the fluorescence in the 
430 nm range (excitation 360 nm) dramatically in- 
creased, whereas in the other parts of the spectrum 
it remained more or less unchanged. This effect of 
auto-oxidation on the 430 nm fluorescence could 
be seen on both total LDL and the apo-B, isolated 
from an auto-oxidized LDL sample. With the lipid 
fraction the fluorescence decreased in the 470 nm 
range and increased in other parts of the spectrum, 
particularly at 410 nm. From FIT analyses, auto- 
oxidized LDL and its apo-B possess an emission 
maximum at 430 nm and an excitation maximum 
at 355 nm. All LDL preparations investigated so 
far responded to auto-oxidation conditions with 
this strong increase of the 430 nm fluorescence. On 
average, the 430 nm fluorescence intensity of auto- 
oxidized LDL and the apo-B isolated therefrom 
LK 
380 L20 L60 5co 
WAVELENGTH tnm) 
Fig.3. Uncorrected emission spectra (a) at 
refer to the 4 LDL preparations shown in 
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360 nm excitation and solvent background corrected FIT (b) of apo-B. 1-4 
fig.2. The FIT was recorded from the apo-B of LDL no.3. (x) As in fig.1. 
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was 3-times higher than in the corresponding con- 
trol sample. 
4. DISCUSSION 
We have focused our interest on the near-UV 
and visible part of the LDL fluorescence spectrum 
(300-500 nm excitation, 390-590 nm emission), 
which is not overshadowed by the strong tryp- 
tophan fluorescence and should therefore be more 
indicative of subtle alterations of the protein and 
lipid domain under physiological or pathophys- 
iological conditions. Human plasma LDL re- 
presents a multicomponent system with several 
fluorescent constituents. The application of 
3-dimensional fluorescence spectroscopy enabled 
us to resolve the diffuse fluorescence of total LDL 
and its lipid and protein fraction into distinct 
peaks or shoulders and to determine the spectral 
properties of the fluorophores contained in LDL. 
The FIT of freshly prepared LDL clearly showed 
the presence of at least 5 fluorescent components. 
Separate analyses of the lipid fraction and the apo- 
B revealed firstly that the number of potential 
fluorophores in normal plasma LDL was much 
higher than detectable by the FIT analysis of the 
total LDL and, secondly, that both the apo-B and 
the lipid fraction contained fluorescent con- 
stituents. The approximate number deduced from 
the FITS was 6 in apo-B and 7 in the lipid fraction. 
The precise assignment of the various excitation 
and emission maxima to specific substances or 
chemical structures was not within the scope of this 
initial work. Vitamin E, a known constituent of 
LDL, fluoresces maximally at 335 nm (excitation 
290 nm) and is therefore outside the FIT range 
measured here. Retinol and vitamin A derivatives 
are most likely responsible for the emission around 
470 nm in the lipid fraction. The 430 nm 
fluorescence (excitation maximum 355 nm) found 
in freshly prepared LDL and its apo-B is most like- 
ly indicative of the presence of remnants from lipid 
peroxidation which had occurred in vivo prior to 
isolation of the LDL from plasma of the donors. 
This assumption is supported by several findings. 
(i) Peroxidation of LDL in vitro reveals a strong 
fluorescence with maximum excitation at 355 nm 
and maximum emission at 430 nm. (ii) LDL 
isolated from aortic tissue was also shown to have 
an intense fluorescence at around 420 nm which 
was tentatively attributed to in vivo lipid peroxida- 
tion [ 11. (iii) It has been reported that LDL is the 
main carrier for plasma lipid peroxides [6]. (iv) 
LDL of the two single donors isolated 
simultaneously and LDL from the pooled plasma 
LDL, all prepared under identical conditions, 
showed different relative fluorescence intensities at 
430 nm indicating variations between different 
individuals. 
The fluorescence at around 430 nm of in vivo or 
in vitro peroxidized biological samples has been 
ascribed to the aminoiminopropene structure 
-N = CH-CH = CH-NH- formed by the interaction 
of the lipid peroxidation product malondialdehyde 
with amino functions in proteins or phospholipids 
[lo]. We have shown that malondialdehyde reacts 
with LDL to give fluorescent products [5]. The ex- 
citation and emission maxima (400/470 nm) were, 
however, not identical with those of the 
fluorophore produced during LDL auto-oxidation 
(355/430 nm). The fluorescence of native or auto- 
oxidized plasma LDL and aortic LDL at 430 nm 
[l] must therefore be ascribed to products which 
are not derived from malondialdehyde. It is known 
[11,12] that a great diversity of reactive aldehydes 
other than malondialdehyde are produced during 
the peroxidative degradation of polyunsaturated 
lipids and it seems reasonable to assume that one 
(or more) of them can interact with proteins or 
lipids [8] to give the 430 nm fluorophore. 
The biological significance of this study lies in 
the possibility of detecting by 3-dimensional 
fluorescence spectroscopy alteration of LDL 
related to peroxidation processes. It has been 
shown that LDL exposed to endothelial cells [7] or 
smooth muscle cells [13] is altered by lipid perox- 
idation, assumes an increased negative charge, 
becomes toxic to fibroblasts and bypasses the 
classical LDL receptor [7]. Many other in vitro and 
in vivo observations (review [8]) suggest but of 
course do not prove that lipid peroxidation of LDL 
is in some way involved in the multi-step process of 
atherogenesis. 
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